Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 210Triple Negative Breast Neoplasms 32Stomach Neoplasms 30Inflammatory Breast Neoplasms 21Esophageal Neoplasms 15Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Liver Neoplasms 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2

Interventions

Cyclophosphamide 31Trastuzumab 30Paclitaxel 28Docetaxel 22Taxes 18Doxorubicin 18Lapatinib 15Radiotherapy 14Capecitabine 14Bevacizumab 13Tamoxifen 12Carboplatin 11Filgrastim 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Chemotherapy, Adjuvant 8exemestane 7Vorinostat 7Letrozole 7Immunohistochemistry 7Gemcitabine 7Anastrozole 7Albumin-Bound Paclitaxel 7pegfilgrastim 6Neoadjuvant Therapy 6Magnetic Resonance Spectroscopy 6Immunoenzyme Techniques 6Goserelin 6Flow Cytometry 6Everolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms, Male × Epirubicin × Clear all
NCT00820547 2019-10-22

Beverly1

UNICANCER

Phase 2 Completed
100 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00301925 2018-08-08

TACT2

Institute of Cancer Research, United Kingdom

Phase 3 Unknown
4,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00176488 2017-03-23

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Rutgers, The State University of New Jersey

Phase 2 Terminated
31 enrolled 6 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01093235 2010-03-25

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms, Postoperative Complications, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡